Sunshine Biopharma (NASDAQ:SBFM) versus Medpace (NASDAQ:MEDP) Head-To-Head Analysis

Sunshine Biopharma (NASDAQ:SBFMGet Rating) and Medpace (NASDAQ:MEDPGet Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

96.9% of Medpace shares are owned by institutional investors. 22.0% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Sunshine Biopharma and Medpace’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sunshine Biopharma N/A N/A N/A
Medpace 15.92% 20.55% 11.89%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sunshine Biopharma and Medpace, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunshine Biopharma 0 0 0 0 N/A
Medpace 0 0 2 0 3.00

Medpace has a consensus price target of $182.63, suggesting a potential upside of 15.52%. Given Medpace’s higher probable upside, analysts plainly believe Medpace is more favorable than Sunshine Biopharma.

Earnings & Valuation

This table compares Sunshine Biopharma and Medpace’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sunshine Biopharma N/A N/A N/A N/A N/A
Medpace $1.14 billion 4.66 $181.85 million $4.81 32.87

Medpace has higher revenue and earnings than Sunshine Biopharma.


Medpace beats Sunshine Biopharma on 8 of the 8 factors compared between the two stocks.

About Sunshine Biopharma (Get Rating)

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

About Medpace (Get Rating)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with's FREE daily email newsletter.